| abstract |
Disclosed herein are methods for treating benign, precancerous or non-metastatic tumors using anti-VEGF specific antagonists. Also disclosed is a method of treating a subject at risk of developing a benign, precancerous or non-metastatic tumor using an anti-VEGF specific antagonist. Also disclosed are methods of treating or preventing tumor recurrence using anti-VEGF specific antagonists, and the use of VEGF specific antagonists in neoadjuvant (adjuvant adjuvant) and adjuvant (adjuvant) cancer therapy. |